Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Net Cash Flow (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Net Cash Flow data on record, last reported at -$2.0 million in Q4 2025.

  • For Q4 2025, Net Cash Flow changed N/A year-over-year to -$2.0 million; the TTM value through Dec 2025 reached $40.0 million, changed N/A, while the annual FY2025 figure was $72.0 million, 213.04% up from the prior year.
  • Net Cash Flow reached -$2.0 million in Q4 2025 per RCUS's latest filing, down from $42.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $401.0 million in Q1 2022 and bottomed at -$276.0 million in Q2 2022.
  • Average Net Cash Flow over 5 years is $4.1 million, with a median of -$12.0 million recorded in 2022.
  • Peak YoY movement for Net Cash Flow: skyrocketed 2228.58% in 2021, then tumbled 375.0% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at -$31.8 million in 2021, then soared by 62.29% to -$12.0 million in 2022, then crashed by 375.0% to -$57.0 million in 2023, then surged by 178.95% to $45.0 million in 2024, then crashed by 104.44% to -$2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$2.0 million in Q4 2025, $42.0 million in Q1 2025, and $45.0 million in Q3 2024.